RPS6KB1 and cancer: Ectopic introduction of RagDGDP or active heterodimer (RagBGTP/RagDGDP), both of which mimic the activated downstream effector of LRS, also compromised the effect of BC-LI-0186, but not rapamycin, on S6K phosphorylation inhibition (Fig. 4f, g), cancer cell growth inhibition, and cell death induction (Supplementary Fig. 5c–e).